Biomarkers in Samples From Young Patients With Neuroblastoma
RATIONALE: Studying samples of tissue and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study studies biomarkers in samples from young patients with neuroblastoma.
Genetic: polymerase chain reaction
Genetic: protein expression analysis
Genetic: western blotting
Other: flow cytometry
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||ROR1 as a Novel Target for Neuroblastoma|
- ROR1 is expressed on the surface of neuroblastoma cells and constitutes a suitable target for mAb therapy [ Designated as safety issue: No ]
|Study Start Date:||May 2011|
|Estimated Primary Completion Date:||January 2100 (Final data collection date for primary outcome measure)|
- To analyze the expression of ROR1 on the surface of primary neuroblastoma cells.
- To investigate the therapeutic potential of anti-ROR1 monoclonal antibodies (mAbs), bispecific antibodies, and immunotoxins in in vitro and in vivo models of neuroblastoma.
OUTLINE: Archived bone marrow and tumor tissue samples are analyzed for ROR1 expression by flow cytometry, western blotting, qPCR, and IHC.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01358604
|Principal Investigator:||David Hema, MD, MPH||NCI - Experimental Transplantation and Immunology Branch|